Market Overview

Alnylam Shares Down 23% Since Mar. 28 Following Pfizer Update On ATTR-ACT; B. Riley FBR Earlier Issued Note Suggesting '8.3% decline in ALNY shares on 3/29 provide a buying opportunity'; Reiterates Buy Rating, $200 Price Target

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for ALNY

DateFirmActionFromTo
Sep 2018Stifel NicolausMaintainsBuyBuy
Aug 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Aug 2018B. Riley FBRMaintainsBuyBuy

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings Movers Trading Ideas

 

Related Articles (ALNY)

Oil ETFs Take A Hit On Sudden Inventory Build

Morgan Stanley: Lululemon Satisfies Necessary Condition For Growth With Expense Guidance